According to FDA, today’s laboratory-developed tests are frequently manufactured using components and instruments that are not legally marketed for clinical use, and often rely on high-technology instrumentation and software to generate results and clinical interpretations.
Read MoreAn agreement between Quotient and OCD assigns MosaiQ commercialization rights in the global patient testing market and donor testing markets in the developing world and Japan, while accelerating launch of the MosaiQ system.
Read More
Featured emerging technologies include a digital pathology image capture platform, an infectious disease testing platform, and an acute kidney injury test.
Read More
After its ASH 2014 debut, the RainDance HemOnc Consortium, an international panel of clinical research experts, will focus on developing assays for liquid biopsy research of myeloid disorders.
Read More
The Centers for Disease Control’s guidelines for testing high-risk specimens include using centrifuges with sealed rotors and a Class II biosafety cabinet.
Read More